Spectrum Pharmaceuticals Highlights Five Abstracts of Clinical Data at the 2015 American Society of Clinical Oncology (ASCO) ...
May 29 2015 - 7:00AM
Business Wire
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI), a biotechnology
company with fully integrated commercial and drug development
operations with a primary focus in Hematology and Oncology, today
announced presentations of clinical data for Beleodaq®
(belinostat), Folotyn® (pralatrexate injection) and Poziotinib to
be presented at the American Society of Clinical Oncology (ASCO)
Annual Meeting, being held in Chicago, Illinois, from May 29 to
June 2, 2015.
For more information about the ASCO Annual Meeting and for a
complete list of abstracts, please refer to the conference Web site
at http://abstract.asco.org/.
Sunday, May 31, 2015, 8:00 AM-11:30 AM
CDT (Poster) and 4:30 PM-5:45 PM CDT (Poster Discussion)
Abstract # Type Title
First Author Location 10516 Poster A
Phase I/II clinical trial of belinostat (PXD101) in combination
with doxorubicin in patients with soft tissue sarcomas (STS).
Joanna Vitfell-Rasmussen S Hall A e13581 Electronic UGT1A1
genotype effects on PK, PD and toxicities of belinostat
administered by 48 h continuous infusion. Andrew K.L Goey
Electronic e18564 Electronic Effect of treatment on the
regression and growth rates of thymic epithelial tumors (TETs).
Mauricio Emmanuel
Burotto Pichun
Electronic
Monday, June 1, 2015, 8:00 AM-11:30 AM
CDT
Abstract # Type Title First
Author Location 8085 Poster A Phase II, single-arm,
efficacy and safety study of poziotinib (NOV120101) in Korean
patients with advanced or metastatic lung adenocarcinoma who have
acquired resistance to epidermal growth factor receptor tyrosine
kinase inhibitors. Ji-Youn Han S Hall A E15037 Electronic A
Phase II trial of pralatrexate (P) plus oxaliplatin (O) in advanced
esophago-gastric cancer (aEGC): survival analysis and
pharmacogenetic correlates. Usha Malhotra Electronic
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company
focused on acquiring, developing, and commercializing drug
products, with a primary focus in hematology and oncology. Spectrum
markets five hematology/oncology drugs, and expects an FDA decision
on another hematology drug later this year. Additionally,
Spectrum's pipeline includes three drugs targeting blockbuster
markets in advanced stages of clinical development. Spectrum's
strong track record in in-licensing and acquiring differentiated
drugs, and expertise in clinical development have generated a
robust, diversified, and growing pipeline of product candidates in
advanced-stage Phase 2 and Phase 3 studies. More information on
Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to our business and its future, including
certain company milestones, Spectrum's ability to identify,
acquire, develop and commercialize a broad and diverse pipeline of
late-stage clinical and commercial products, leveraging the
expertise of partners and employees around the world to assist us
in the execution of our strategy, and any statements that relate to
the intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that our existing and new drug candidates may not prove safe or
effective, the possibility that our existing and new applications
to the FDA and other regulatory agencies may not receive approval
in a timely manner or at all, the possibility that our existing and
new drug candidates, if approved, may not be more effective, safer
or more cost efficient than competing drugs, the possibility that
our efforts to acquire or in-license and develop additional drug
candidates may fail, our lack of sustained revenue history, our
limited marketing experience, our dependence on third parties for
clinical trials, manufacturing, distribution and quality control
and other risks that are described in further detail in the
Company's reports filed with the Securities and Exchange
Commission. We do not plan to update any such forward-looking
statements and expressly disclaim any duty to update the
information contained in this press release except as required by
law.
SPECTRUM PHARMACEUTICALS, INC.®, FUSILEV®, FOLOTYN®, ZEVALIN®,
MARQIBO®, and BELEODAQ® are registered trademarks of Spectrum
Pharmaceuticals, Inc and its affiliates. REDEFINING CANCER CARE™,
EVOMELA™ and the Spectrum Pharmaceuticals logos are trademarks
owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are
the property of their respective owners.
© 2015 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150529005041/en/
Spectrum Pharmaceuticals, Inc.Shiv KapoorVice President,
Strategic Planning & Investor
Relations702-835-6300InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024